The omentum is a common site of metastasis for various cancers like ovarian, gastric, colorectal, and pancreatic cancers due to complex mechanisms including anatomic features, cellular interactions, and immune system responses.
Metastatic niche development involves detachment from the primary tumor, survival in the peritoneal cavity, migration to the omentum, adhesion, invasion, and proliferation.
The omental structure, circulation of peritoneal fluid, immune cell-rich 'milky patches', and adhesion molecules like CD44 and integrins contribute to the metastatic process.
Adipocytes in the omentum provide energy sources and signaling molecules to support tumor growth, while stromal cells stimulate angiogenesis and cancer cell proliferation.
Tumor-associated macrophages (TAMs) and M2 macrophages in the omentum promote metastatic growth by facilitating angiogenesis, ECM remodeling, and immune evasion.
Neutrophils, influenced by factors like G-CSF, prepare the metastatic niche through NETosis, creating structures that aid in cancer cell capture and spread to other parts of the body.
G-CSF triggers neutrophil migration into the omentum, leading to the formation of 'pre-metastatic niche'; G-CSF, IL-8, and GRO induce NETosis in neutrophils, aiding in metastasis.
NETs act as traps for circulating cancer cells, promoting their adhesion to the omentum; the NET structures play a crucial role in the omental metastatic cascade.
The physical trapping and anchoring function of NETs, along with proteolytic enzymes on NETs, facilitate cancer cell invasion and remodeling of the extracellular matrix, promoting metastatic growth.
The diverse mechanisms involved in omental metastasis underscore the complexity of the process, necessitating consideration of anatomical, cellular, and immune components for developing targeted therapies.
The dual role of G-CSF in neutropenia treatment and omental metastasis highlights the importance of carefully evaluating its use in patients at risk of metastasis; targeting NET formation could be a potential approach for future cancer treatments.